Cellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
Infect Genet Evol. 2020 Nov;85:104580. doi: 10.1016/j.meegid.2020.104580. Epub 2020 Oct 3.
The non-classical human leukocyte antigens (HLA)-G could be generally considered as a potent tolerogenic molecule, which modulates immune responses. HLA-G due to the immunosuppressive properties may play an important role in the pathogenesis of infections related to the liver. HLA-G may display two distinct activities in the pathological conditions so that it could be protective in the autoimmune and inflammatory diseases or could be suppressive of the immune system in the infections or cancers. HLA-G might be used as a novel therapeutic target for liver diseases in the future. Indeed, new therapeutic agents targeting HLA-G expression or antibodies which block HLA-G activity are being developed and tested. However, further consideration of the HLA-G function in liver disease is required. This review aims to summarize the role of HLA-G in the liver of patients with HBV infection.
非经典人类白细胞抗原（HLA）-G 通常被认为是一种有效的免疫耐受分子，可调节免疫反应。由于具有免疫抑制特性，HLA-G 在与肝脏相关的感染发病机制中可能发挥重要作用。在病理条件下，HLA-G 可能表现出两种不同的活性，因此在自身免疫和炎症性疾病中可能具有保护作用，而在感染或癌症中可能抑制免疫系统。HLA-G 将来可能被用作肝脏疾病的新的治疗靶点。事实上，目前正在开发和测试针对 HLA-G 表达的新型治疗药物或阻断 HLA-G 活性的抗体。然而，需要进一步考虑 HLA-G 在肝脏疾病中的功能。本综述旨在总结 HLA-G 在 HBV 感染患者肝脏中的作用。
